Home › Research › Biomarkers
[Neurology : what's new in 2025]
Andria Tziakouri, Valentin Loser, Alex Vicino, Thomas Baumgartner, Giovanni Di Liberto, Vasiliki Pantazou, Raphaël Bernard-Valnet, Marie Theaudin et al.. Revue medicale suisse, 2026-01-21
Topic: Drug trials: efficacy and safety
In 2025, several major advances have marked the field of neurology. Anti-FcRN and anti-C5 antibodies have confirmed their long-term efficacy in the treatment of myasthenia gravis. Bruton tyrosine kinase inhibitors have expanded the therapeutic arsenal for multiple sclerosis. An antibody targeting α-synuclein appears to slow motor decline in early-stage Parkinson's disease. The efficacy of late thrombolysis in strokes with radiological mismatch has been confirmed. A blood biomarker facilitates early detection of Alzheimer's disease, and Swiss guidelines specify the modality for the use of anti-amyloid therapies in this disease. Finally, in pregnant women with epilepsy, the recommended dose of folic acid has been reduced.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tziakouri, A., Loser, V., Vicino, A., Baumgartner, T., Di Liberto, G., Pantazou, V., et al. (2026). [Neurology : what's new in 2025]. Revue medicale suisse. https://doi.org/10.53738/revmed.2026.22.946.48114
Vancouver
Tziakouri A, Loser V, Vicino A, Baumgartner T, Di Liberto G, Pantazou V, et al. [Neurology : what's new in 2025]. Revue medicale suisse. 2026. doi:10.53738/revmed.2026.22.946.48114. PMID: 41567052.
BibTeX
@article{tziakouri2026-41567052,
author = {Tziakouri, Andria and Loser, Valentin and Vicino, Alex and Baumgartner, Thomas and Di Liberto, Giovanni and Pantazou, Vasiliki and Bernard-Valnet, Raphaël and Theaudin, Marie and others},
title = {{[Neurology : what's new in 2025]}},
journal = {Revue medicale suisse},
year = {2026},
doi = {10.53738/revmed.2026.22.946.48114},
pmid = {41567052},
url = {https://doi.org/10.53738/revmed.2026.22.946.48114}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Bruton tyrosine kinase inhibitors have expanded the therapeutic arsenal for multiple sclerosis.
- An antibody targeting α-synuclein appears to slow motor decline in early-stage Parkinson's disease.
- The efficacy of late thrombolysis in strokes with radiological mismatch has been confirmed.
- A blood biomarker facilitates early detection of Alzheimer's disease, and Swiss guidelines specify the modality for the use of anti-amyloid therapies in this disease.
- Finally, in pregnant women with epilepsy, the recommended dose of folic acid has been reduced.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 25 of the 56 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Revue medicale suisse) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41567052) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 25 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 25 of the 56 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Biomarkers
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.